Portola Pharmaceuticals Inc. (PTLA)

26.64
NASDAQ : Health Technology
Prev Close 26.88
Day Low/High 26.58 / 27.08
52 Wk Low/High 14.81 / 42.17
Avg Volume 974.10K
Exchange NASDAQ
Shares Outstanding 68.11M
Market Cap 1.83B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Here’s Why Portola Pharmaceuticals (PTLA) Stock is Falling Today

Here’s Why Portola Pharmaceuticals (PTLA) Stock is Falling Today

Portola Pharmaceuticals (PTLA) stock is dropping late Monday afternoon as Goldman Sachs downgraded the stock and the company reported disappointing trial results last week.

Portola Pharmaceuticals (PTLA) Weak On High Volume Today

Portola Pharmaceuticals (PTLA) Weak On High Volume Today

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a weak on high relative volume candidate

Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today

Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today

Portola Pharmaceuticals (PTLA) stock is tumbling on heavy trading volume on Thursday afternoon the company said its oral treatment for blood clots is not statistically different than the current standard.

Portola Pharmaceuticals (PTLA) Stock Falls on Blood Clot Trial Results

Portola Pharmaceuticals (PTLA) Stock Falls on Blood Clot Trial Results

Portola Pharmaceuticals (PTLA) stock is down after the company said its oral treatment for blood clots was not statistically different than the current standard of care.

Heavy Trading On Portola Pharmaceuticals (PTLA) Before Market Open

Heavy Trading On Portola Pharmaceuticals (PTLA) Before Market Open

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a pre-market mover with heavy volume candidate

Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

Portola Pharmaceuticals Enters Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To $120 Million

Portola Pharmaceuticals Enters Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To $120 Million

Portola Retains Full Worldwide Commercial Rights to Andexanet Alfa Outside of Japan

Portola Pharmaceuticals To Webcast Corporate Update On January 12, 2016

Portola Pharmaceuticals To Webcast Corporate Update On January 12, 2016

Two Products in Thrombosis Franchise Expected to Launch in Next 18 Months

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

The New England Journal Of Medicine Publishes Results Of Portola Pharmaceuticals' Phase 3 ANNEXA Studies Of Andexanet Alfa

The New England Journal Of Medicine Publishes Results Of Portola Pharmaceuticals' Phase 3 ANNEXA Studies Of Andexanet Alfa

Full Data Set From ANNEXA-R Also Presented Today in Late-Breaking Clinical Trial Session at AHA Scientific Sessions 2015

Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015

Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015

Full Results of Andexanet Alfa and Rivaroxaban Part 2 Study to be Featured in Late-Breaking Clinical Trial Oral Session on November 11th

Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients

Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients

Betrixaban Has Potential to Become First Oral Factor Xa Inhibitor Anticoagulant Approved for Hospital-to-Home Prevention of Venous Thromboembolism in Acute Medically Ill Patients

Portola Pharmaceuticals (PTLA) In A Perilous Reversal

Portola Pharmaceuticals (PTLA) In A Perilous Reversal

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "perilous reversal" (up big yesterday but down big today) candidate

TheStreet Quant Rating: D- (Sell)